Literature DB >> 31010457

Nonalcoholic Fatty Liver Disease: An Update on the Diagnosis.

Jia-Zhen Zhang1, Jing-Jing Cai2, Yao Yu3, Zhi-Gang She1, Hongliang Li1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a common liver disease and a major cause of related complications such as cirrhosis and hepatocellular carcinoma (HCC). NAFLD progresses through the stages of simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and HCC. However, NAFLD usually cannot be diagnosed in a timely manner, which is largely attributed to the asymptomatic features of NAFLD patients and the lack of an effective and accurate noninvasive screening approach. Although liver biopsy has been recognized as a gold standard for diagnosing NAFLD, this approach is not suitable for screening and monitoring NAFLD because of its high cost and invasiveness. Several noninvasive screening and diagnostic systemic assessments have been developed in recent years for NAFLD evaluation. Here we summarize the current status and methods for NAFLD diagnosis, including both noninvasive (imaging, biomarkers) and invasive (liver biopsy) assessments. We further discuss the advantages and disadvantages of these developed diagnostic approaches for NAFLD.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31010457      PMCID: PMC6827037          DOI: 10.3727/105221619X15553433838609

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  105 in total

1.  Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population.

Authors:  Lidia S Szczepaniak; Pamela Nurenberg; David Leonard; Jeffrey D Browning; Jason S Reingold; Scott Grundy; Helen H Hobbs; Robert L Dobbins
Journal:  Am J Physiol Endocrinol Metab       Date:  2004-08-31       Impact factor: 4.310

Review 2.  Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies.

Authors:  Siddharth Singh; Alina M Allen; Zhen Wang; Larry J Prokop; Mohammad H Murad; Rohit Loomba
Journal:  Clin Gastroenterol Hepatol       Date:  2014-04-24       Impact factor: 11.382

Review 3.  Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography.

Authors:  Eugenia Tsai; Tai-Ping Lee
Journal:  Clin Liver Dis       Date:  2018-02       Impact factor: 6.126

Review 4.  Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment.

Authors:  Vincent Wai-Sun Wong; Wah-Kheong Chan; Shiv Chitturi; Yogesh Chawla; Yock Young Dan; Ajay Duseja; Jiangao Fan; Khean-Lee Goh; Masahide Hamaguchi; Etsuko Hashimoto; Seung Up Kim; Laurentius Adrianto Lesmana; Yu-Cheng Lin; Chun-Jen Liu; Yen-Hsuan Ni; Jose Sollano; Simon Kin-Hung Wong; Grace Lai-Hung Wong; Henry Lik-Yuen Chan; Geoff Farrell
Journal:  J Gastroenterol Hepatol       Date:  2018-01       Impact factor: 4.029

Review 5.  Non-alcoholic fatty liver disease - A global public health perspective.

Authors:  Zobair M Younossi
Journal:  J Hepatol       Date:  2018-11-09       Impact factor: 25.083

6.  Hepatic MR Elastography: Clinical Performance in a Series of 1377 Consecutive Examinations.

Authors:  Meng Yin; Kevin J Glaser; Jayant A Talwalkar; Jun Chen; Armando Manduca; Richard L Ehman
Journal:  Radiology       Date:  2015-07-08       Impact factor: 11.105

7.  Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis.

Authors:  Fernando Bril; Romina Lomonaco; Beverly Orsak; Carolina Ortiz-Lopez; Amy Webb; Fermin Tio; Joan Hecht; Kenneth Cusi
Journal:  Hepatology       Date:  2014-04-25       Impact factor: 17.425

8.  Noninvasive assessment of liver fibrosis with combined serum aminotransferase/platelet ratio index and hyaluronic acid in patients with chronic hepatitis B.

Authors:  You-Xiang Zhang; Wen-Juan Wu; Yun-Zhi Zhang; Yan-Ling Feng; Xin-Xi Zhou; Qi Pan
Journal:  World J Gastroenterol       Date:  2008-12-14       Impact factor: 5.742

9.  Vinexin β Ablation Inhibits Atherosclerosis in Apolipoprotein E-Deficient Mice by Inactivating the Akt-Nuclear Factor κB Inflammatory Axis.

Authors:  Hongjing Guan; Wen-Lin Cheng; Junhong Guo; Meng-Lin Chao; Yan Zhang; Jun Gong; Xue-Yong Zhu; Zhi-Gang She; Zan Huang; Hongliang Li
Journal:  J Am Heart Assoc       Date:  2017-02-16       Impact factor: 5.501

Review 10.  Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions.

Authors:  Andrew Ofosu; Daryl Ramai; Madhavi Reddy
Journal:  Ann Gastroenterol       Date:  2018-02-23
View more
  2 in total

Review 1.  MAFLD/NAFLD Biopsy-Free Scoring Systems for Hepatic Steatosis, NASH, and Fibrosis Diagnosis.

Authors:  Nancy de Los Ángeles Segura-Azuara; Carlos Daniel Varela-Chinchilla; Plinio A Trinidad-Calderón
Journal:  Front Med (Lausanne)       Date:  2022-01-13

2.  Nonalcoholic fatty liver disease impacts the control of the international normalized ratio in patients with atrial fibrillation.

Authors:  Xi Zhang; Guang-Yu Chen; Zhao-Xia Wang; Xue-Hai Li; Rong Luo; Yi-Gang Li; Fan Yang; Xin Zhou; Feng Jiang; Yao-Sheng Wang
Journal:  Ann Transl Med       Date:  2020-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.